VistaGen Therapeutics, Inc. (VTGN)

Market Cap	30.06M
Revenue (ttm)	-363,900
Net Income (ttm)	-63.71M
Shares Out	232.67M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,317,372
Open	0.140
Previous Close	0.138
Day's Range	0.125 - 0.140
52-Week Range	0.080 - 1.790
Beta	1.10
Analysts	Sell
Price Target	0.20 (+54.8%)
Earnings Date	Feb 7, 2023

About VTGN

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: VTGN

Financial Performance

In 2022, VTGN's revenue was $1.11 million, an increase of 1.78% compared to the previous year's $1.09 million. Losses were -$48.71 million, 15.1% more than in 2021.

Analyst Forecast

According to 7 analysts, the average rating for VTGN stock is "Sell." The 12-month stock price forecast is $0.2, which is an increase of 54.80% from the latest price.

Price Target

$0.2

(54.80% upside)

Analyst Consensus: Sell